QUANTITATIVE CHANGES IN RETINAL PIGMENT EPITHELIAL DETACHMENTS AS A PREDICTOR FOR RETREATMENT WITH ANTI-VEGF THERAPY

Purpose: To determine if quantitative changes in retinal pigment epithelial detachments (PEDs) predict the need for retreatment in eyes undergoing spectral domain optical coherence tomography (SD OCT)–guided as-needed therapy with anti–vascular endothelial growth factor drugs. Methods: Patients with vascularized PEDs undergoing SD OCT–guided treatment with anti–vascular endothelial growth factor drugs were retrospectively identified. The decision to retreat these cases was based on qualitative assessments of fluid in the macula. Spectral domain OCT images from visits in which the treatment was withheld were retrospectively analyzed. A novel algorithm was then used to measure the area and volume of PEDs at these visits. Results: Fourteen eyes were identified, and retreatment was withheld at 57 visits. When the SD OCT algorithm was used to evaluate the scans from these visits, the PED volume increased at eight visits. At all of these eight visits, a treatment was needed at the next follow-up visit. For the remaining 49 visits in which the treatment was withheld, the PED volume did not increase and no treatment was needed at the next follow-up visit. Conclusion: Quantitation of the change in the PED volume and area may be useful in determining when to retreat eyes undergoing SD OCT–guided as-needed anti–vascular endothelial growth factor therapy.

[1]  Philip J Rosenfeld,et al.  A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study. , 2009, American journal of ophthalmology.

[2]  H. Loi,et al.  Myositis Ossificans , 2011, The western journal of emergency medicine.

[3]  K. Eng,et al.  Ranibizumab in neovascular age-related macular degeneration , 2006, Clinical interventions in aging.

[4]  William J Feuer,et al.  Natural history of drusen morphology in age-related macular degeneration using spectral domain optical coherence tomography. , 2011, Ophthalmology.

[5]  N. Bressler Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials-tap report 2. , 2001 .

[6]  J. Duker,et al.  Optical coherence tomography of age-related macular degeneration and choroidal neovascularization. , 1996, Ophthalmology.

[7]  Irene Barbazetto,et al.  Photodynamic therapy of subfoveal choroidal neovascularization with verteporfin: fluorescein angiographic guidelines for evaluation and treatment--TAP and VIP report No. 2. , 2003, Archives of ophthalmology.

[8]  J. Gass,et al.  Pathogenesis of tears of the retinal pigment epithelium. , 1984, The British journal of ophthalmology.

[9]  Glenn J Jaffe,et al.  Ranibizumab and bevacizumab for neovascular age-related macular degeneration. , 2011, The New England journal of medicine.

[10]  Gabriel Coscas,et al.  Optical coherence tomography identification of occult choroidal neovascularization in age-related macular degeneration. , 2007, American journal of ophthalmology.

[11]  B. Lujan,et al.  Spectral domain optical coherence tomography imaging of drusen in nonexudative age-related macular degeneration. , 2011, Ophthalmology (Rochester, Minn.).

[12]  William J Feuer,et al.  Quantitative imaging of retinal pigment epithelial detachments using spectral-domain optical coherence tomography. , 2012, American journal of ophthalmology.

[13]  Anat Loewenstein,et al.  Retinal pigment epithelial detachment. , 2007, Survey of ophthalmology.